Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
Sight Sciences executive Brenton Taylor, EVP of Operations & R&D, reported a small sale of company stock mainly to cover taxes from vesting equity. On January 6, 2026, he sold 619 shares of Sight Sciences common stock at a weighted average price of $7.48 per share, through multiple trades priced between $7.39 and $7.67. After this tax-related sale, he directly holds 170,212 shares of the company’s common stock.
Sight Sciences insider Jeremy Hayden has filed a notice of proposed stock sales under Rule 144. The filing states an intention to sell 1,785 shares of Sight Sciences common stock through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of January 6, 2026 and an aggregate market value of $13,354.66. These shares were acquired on January 2, 2026 via restricted stock vesting from the issuer as compensation.
The notice also lists recent sales over the prior three months by the same seller, including 3,150 shares sold on November 12, 2025 for gross proceeds of $25,227.78, 44,850 shares sold on November 25, 2025 for $362,596.77, and 9,385 shares sold on January 5, 2026 for $73,418.85. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the company.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 13,958 shares of common stock on 12/16/2025 at a weighted average price of $8.308 per share. The shares were bought in multiple trades at prices ranging from $8.12 to $8.40.
After this transaction, Encrantz directly beneficially owns 1,391,922 shares, which include 30,952 restricted stock units subject to vesting. He is also reported as having indirect beneficial ownership of 632,456 shares held by a revocable trust where he serves as trustee, and 5,086,920 shares held by Allegro Investment Fund, L.P., although he disclaims pecuniary interest and beneficial ownership in the Allegro-held shares.
Sight Sciences, Inc. (SGHT) reported an insider transaction by its EVP, Operations & R&D, Brenton Taylor. On 11/17/2025, Taylor sold 14,418 shares of common stock at a weighted average price of $7.06 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units. After this transaction, Taylor beneficially owned 170,831 shares of Sight Sciences common stock.
Sight Sciences, Inc. (SGHT) filed a Form 4 reporting equity transactions by Chief Legal Officer Jeremy Hayden. On 11/12/2025, he exercised stock options for 2,440 shares of common stock at $1.96 per share and an additional 710 shares at the same exercise price, all under the company’s equity incentive plan.
The same day, 3,150 shares of common stock were sold at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06. Following these transactions, Hayden beneficially owned 256,590 shares of common stock directly. The filing states the transactions were made under a Rule 10b5-1 trading plan tied to a marital separation agreement, and that his former spouse will receive all proceeds from the share sales.
Sight Sciences (SGHT) reported an insider equity grant. Chief Operating Officer Alison Bauerlein acquired 23,006 RSUs on November 11, 2025 under the company’s 2021 Incentive Award Plan at a stated price of $0 per unit. The award equals approximately $150,000 of common stock based on the grant-date price, with each RSU representing one share.
The RSUs vest in 16 equal quarterly installments from December 31, 2025 through September 30, 2029, contingent on continued service. Following this grant, Bauerlein beneficially owned 620,526 shares directly.
Sight Sciences (SGHT) disclosed a Form 4 for its Chief Financial Officer, reporting an equity award tied to service. On November 11, 2025, the officer acquired 15,337 shares of common stock at $0, reflecting settlement of a new grant of restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan. Following the transaction, the officer beneficially owns 161,363 shares, held directly.
The RSU grant equals approximately $100,000 of common stock based on the grant-date price and vests in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Each RSU represents the right to receive one share of common stock and has no expiration date.
Sight Sciences (SGHT) reported an officer’s initial beneficial ownership on Form 3 effective 11/05/2025. The Chief Financial Officer beneficially owns 146,026 shares, including 28,252 shares of common stock and 117,774 restricted stock units subject to vesting conditions. Derivative holdings include stock options for 27,500 shares at $10.96 expiring 05/24/2031, 13,100 shares at $17.52 expiring 02/08/2032, and 14,400 shares at $9.78 expiring 03/16/2033, each with time-based monthly vesting as described.
Sight Sciences (SGHT) reported Q3 2025 results with revenue of $19.9 million, slightly lower than $20.2 million a year ago, as Surgical Glaucoma held steady and Dry Eye remained soft. Gross profit was $17.2 million while operating expenses fell to $25.1 million, narrowing the net loss to $8.2 million from $11.1 million. For the nine months, revenue was $57.0 million and net loss was $34.3 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, down from $120.4 million at year-end, reflecting operating cash outflows. Long-term debt stood at $40.1 million. The company amended its Hercules loan in September, extending the interest-only period to February 1, 2027 and increasing potential incremental tranches (subject to lender approval) while maintaining the $65 million facility.
Management executed a targeted restructuring in Q3, recording $2.8 million of charges to reduce operating expenses. Subsequent to quarter-end, two Medicare Administrative Contractors set jurisdiction-wide pricing for CPT 0563T tied to TearCare, effective retroactive to January 1, 2025. A prior $34 million jury verdict in patent litigation awaits judgment and may be affected by USPTO reexaminations.
Sight Sciences (SGHT) reported leadership changes and furnished Q3 updates. The company promoted Alison Bauerlein to Chief Operating Officer, effective November 5, 2025; she will serve as Principal Operating Officer and cease serving as CFO, Treasurer, Principal Financial Officer and Principal Accounting Officer.
James (Jim) Rodberg was promoted to Chief Financial Officer and Treasurer, also effective November 5, 2025, and will serve as Principal Financial and Accounting Officer. Bauerlein’s compensation includes a $485,000 base salary, a cash bonus target at 65% of salary, and RSUs valued at $150,000 vesting in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Rodberg’s terms include a $400,000 base salary, a 50% bonus target, and $100,000 in RSUs with the same vesting schedule.
Brenda Becker and Erica Rogers resigned from the Board effective November 4, 2025, stating no disagreement with the company. The Board size was reduced from nine to seven, and Catherine Mazzacco was reassigned to Class I with a term ending at the 2028 annual meeting. The company furnished an earnings press release and a leadership press release, and posted an investor presentation.